Laura Graham, MD
Assistant Professor, Medicine-Medical Oncology

Photo
Medical School:
  • MD, Rush Medical College of Rush University Medical Center (2015)
Undergraduate School:
  • BA, University of Chicago (IL) (2009)
Residency:
  • University of Washington Program, Internal Medicine (2018)
Fellowships:
  • University of Washington Program, Cancer / Oncology (2021)
Department: Medicine-Medical Oncology

Professional Titles

  • Assistant Professor

Recognition & Awards

  • Young Investigator Award, American Society of Clinical Oncology (2021)
  • Chief Fellow, Fred Hutchinson Cancer Research Center (2020)
  • Alpha Omega Alpha Medical Honor Society, Medical Honor Society (2015)

Research Interests

I am interested in translational and clinical research in patients with genitourinary cancers, with a particular focus on biomarker development and novel therapeutics. I was granted an ASCO Young Investigator Award to study how patients with prostate cancer who have certain genetic markers respond to therapy.

Teaching

  • Assistant Professor (2021)
    School of Medicine, Medicine

Publications

  • Graham LS, Schweizer MT. Mismatch repair deficiency and clinical implications in prostate cancer. Prostate. 2022 Aug;82 Suppl 1:S37-S44. PubMed PMID: 35358351
  • Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):388-396. PubMed PMID: 34363009
  • Graham LS, Sokolova AO, Khaki AR, Wu QV, Davidson NE. Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Investigation. 2020 Nov 11:1-4.
  • Graham L, Reder N, Gulati R, Grivas P, Wright J, Yu E, Hou W, Nega K, Yezefski T, Montgomery RB, Mostaghel E, Ellis W, True L, Lin D, Nelson P, Schweizer M. Targeting Backdoor Androgen Synthesis Through AKR1C3 Inhibition: A Presurgical Hormonal Ablative Neoadjuvant Trial in High Risk Localized Prostate Cancer. The Prostate. 2021 Mar: 1-9.
  • Koshkin V, Patel V, Ali A, Bilen M, Ravindranathan D, Park J, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham L, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen S, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Marshall C, Tagawa S, Heath E, Haalbi S, Schweizer M, Armstrong A, Dorff T, Alva A. McKay R. PROMISE: A Real World Clinical-Genomic Database to Address Knowledge Gaps in Prostate Cancer. Prostate Cancer and Prostatic Diseases. 2021 July.
  • Graham L, Prtichard C, Schweizer M. Hypermutation, Mismatch Repair Deficiency and Defining Predictors of Response to Checkpoint Blockade. Clinical Cancer Research. 2021 Sep 27
  • Graham LS, Pritchard CC, Schweizer MT. Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. Clin Cancer Res. 2021 Dec 15;27(24):6662-6665. PubMed PMID: 34580112
  • Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 May;81(7):418-426. PubMed PMID: 33755225
  • Graham LS, Sokolova AO, Khaki AR, Wu QV, Davidson NE. Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Invest. 2021 Jan;39(1):21-24. PubMed PMID: 33131319
  • Graham L, Montgomery B, Cheng H, Yu E, Nelson P, Pritchard C, Erickson S, Alva A, Schweizer M. Mismatch Repair Deficiency in Metastatic Prostate Cancer (PC): Response to PD-1 Blockade and Standard Therapies. PLoSOne. 2020 May: 15(5). DOI: 10.1371
  • Graham L, Schade G, Schweizer M. Multimodality Treatment of Bilateral Wilms Tumor in a Pregnant Female. Urology. 2019 Sep. DOI: 10.1016
  • Graham L, True L, Schweizer MT. Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review. Clinical Genitourinary Cancer. 2018 Apr;16(2):e335-e338
  • Graham L, Banda K, Torres A, Pisano K, Shelley G, Curley T, Scher H, Lotan T, Hsieh A, Rathkopf D. A Phase II Study of the Dual mTOR inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Investigational New Drugs. 2018 Jun;36(3):458-467
  • Graham L, Schwartz E, Wilson N, Ording J, Daley K, Khandan S, Lake J, Grinder C, Wood-Molo M, Kent PM. Fertility Preservation in Adolescents and Young Adults with Cancer: Patient Behavior and Provider Attitudes. Women’s Reproductive Health. 2017 March; 4 (1): 1-13
  • Graham L, Schweizer MT. Targeting Persistent Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. Med Oncol. 2016 May; 33 (5): 44
  • Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, Antonopoulos D, Umesaki Y, Chervonsky AV. Gender Bias in Autoimmunity is Influenced by Microbiota. Immunity. 2013 Aug 22;39(2):400–12
  • Graham L, Krass L, Zariffard MR, Spear GT, Mirmonsef P. Effects of Succinic Acid and Other Microbial Fermentation Products on HIV Expression in Macrophages. Biores Open Access. 2013 Oct;2(5):385–91
View All (17 Total) View Less

Practice Locations

UCHealth Tony Grampsas Urologic Cancer Care Clinic - Anschutz Medical Campus
1665 Aurora Ct
1st Floor
Aurora, CO 80045
720-848-0170

Specialty Information

Specialties
  • Medical Oncology, Board Certification (2021)
  • Internal Medicine, Board Certification (2018)
  • ABIM Board Certification in Medical Oncology, Board Certification (2021)
  • ABIM Board Certification in Internal Medicine, Board Certification (2018)
Conditions & Treatments
  • Cancers
  • Cancers - Kidney Cancer
  • Cancers - Prostate Cancer
  • Cancers - Testicular Cancer
  • Cancers - Urologic Cancer
  • Cancers - Bladder Cancer
Care Philosophy
I am committed to providing outstanding evidence-based and compassionate patient care and advancing the science of oncology. I specialize in genitourinary (GU) cancers (Prostate, Bladder, Testicular, Penile, and Kidney Cancers) as well as adrenal cortical carcinoma. We strive to provide patient-focused, personalized, multi-disciplinary care for patients with GU cancers. I collaborate closely with specialized colleagues in a variety of disciplines to provide excellent care and achieve the best outcomes for our patients. We have weekly GU cancer tumor boards, where our specialists come together to discuss patients and patient care.

General Information

Medical Schools:
  • MD, Rush Medical College of Rush University Medical Center (2015)
Undergraduate Schools:
  • BA, University of Chicago (IL) (2009)
Residency Programs:
  • University of Washington Program, Internal Medicine (2018)
Fellowships:
  • University of Washington Program, Cancer / Oncology (2021)
Department: Medicine-Medical Oncology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;